MSCT灌注成像评价索拉非尼治疗肝癌的实验和临床应用研究
|
摘要
第一部分兔VX2肝种植瘤模型的建立及该模型不同生长期的MSCT灌注特点
目的：通过对兔肝脏种植VX2瘤株建立动物模型,为后续研究提供实验基础。并对该模型不同生长期的MSCT灌注参数进行研究,为MSCT灌注成像成为评价该肿瘤生长的影像学手段提供实验依据。
方法：10只新西兰大白兔,采用动物后肢皮下注射接种传代保存瘤种。然后采用开腹瘤块包埋法将其种植于兔肝左叶上。分别于种瘤前、种瘤后第1wk、2wk和第3wk行MSCT灌注扫描,对比种瘤前肝实质与种瘤后肿瘤区域以及第2wk肿瘤区与非肿瘤区肝脏的肝血流量(HBF)、肝血容积(HBV)、平均通过时间(MTT)、毛细血管表面通透性(PS)和肝动脉分数(HAF)的变化规律。种瘤后第3wk于CT检查完成后处死实验兔,进行肝脏病理学检查。所有结果均进行统计学分析。
结果：所有10只新西兰大白兔均成功建立了兔VX2肝种植瘤模型。瘤灶在CT平扫上表现为低密度,增强后病灶强化不明显,边界较清楚。肿瘤部位种瘤后1至3周HBF、PS、HAF、HBV值与种瘤前比较差异均有显著性意义(P<0.01)。种瘤后第2周,肿瘤区HBF、HBV、PS、HAF增高,与非肿瘤区肝组织比较差异有显著性意义(P<0.01)。肿瘤区MTT降低与非肿瘤区肝组织比较差异有显著性意义(P<0.01)。大体病理检查共发现10个单发肿瘤,其中8例中心出现坏死囊变区,与CT检查基本一致。光学低倍镜下见肿瘤细胞在肝内呈浸润性癌巢,与肝实质无明显边界,新生毛细血管丰富；高倍镜下可见瘤细胞体积大,呈不规则排列,核分裂像多见。
结论：采用瘤块种植制备的兔肝VX2肿瘤模型,同时具有容易制备、生长周期短、成功率高及模型稳定等特点,是一种较理想的肝肿瘤实验动物模型,是我们进行基础与临床研究很好的选择。MSCT灌注成像能较好地评价兔VX2肝种植瘤模型的血流动力学变化,结合组织学的研究则可以提供更多的量化信息。
第二部分兔VX2肝种植瘤索拉非尼治疗前、后的血管生成与细胞凋亡的实验研究
目的：通过对兔VX2肝种植瘤模型应用索拉非尼前后的CT灌注参数与组织学进行研究,探索应用CT灌注成像这种影像学手段来评价肿瘤新生血管生成的可行性,同时为索拉非尼抑制肿瘤血管生成并促进肿瘤细胞凋亡的临床效果提供实验依据。
方法：12只新西兰大白兔,采用开腹瘤块包埋法建立兔VX2肝种植瘤模型,2只建模后处死作为病理对照,其余10只于种瘤后第14d行多层螺旋CT灌注扫描,然后经口给予索拉非尼(20mg/kg/d) 7d,种瘤后第21d再次行CT检查,两次扫描肿瘤区所获得的参数值进行比较。检查完成后处死实验兔,进行细胞凋亡(Caspase-3)免疫组织化学染色。
结果：12只兔均接种成功。两次扫描肿瘤区所获得的参数HBF、PS和HAF值比较差异有显著性意义(P<0.01),HBV、MTT值差异无显著性意义。Caspase-3阳性细胞主要分布于中央静脉及肝细胞坏死灶周围。Caspase-3表达强度明显高于对照组(P<0.05)。
结论：CT灌注成像可以评价肿瘤新生血管的生成,而结合了组织学的研究则可以更加明确索拉非尼抑制肿瘤血管生成并促进肿瘤细胞凋亡的作用。
第三部分TACE联合索拉非尼治疗兔VX2肝种植瘤的MSCT灌注与病理及免疫组化对照研究
目的：通过对兔VX2肝种植瘤模型应用TACE联合索拉非尼前后的CT灌注参数与组织学进行研究,探讨通过应用抑制肿瘤血管生成药物以进一步提高TACE疗效方法的可行性。
方法：30只新西兰大白兔建立兔VX2肝种植瘤模型,将模型兔随机分成A、B、C三组,每组10只。A组为生理盐水对照组,B组为TACE治疗组,C组为TACE+索拉非尼联合治疗组。VX2肝种植瘤模型兔于治疗前(治疗时间选择接种VX2肿瘤组织2wk)及治疗后第1、2、3wk行CT平扫观察肿瘤生长情况。于治疗前与治疗后第3wk行CT灌注扫描并记录肿瘤的肝血流量(HBF)、肝血容积(HBV)、平均通过时间(MTT)、毛细血管表面通透性(PS)和肝动脉分数(HAF)等参数值。然后处死实验兔,进行病理以及血管内皮生长因子(vascular endothelial growth factor, VEGF)与CD34免疫组织化学染色。检测VEGF与CD34的表达情况,并在高倍视野下(×400)计算肿瘤细胞VEGF染色阳性率及微血管密度(micro vessel density, MVD)。
结果：治疗后不同时期各组两两比较肿瘤大小与肿瘤生长率均有显著性差异(P<0.01)。VEGF染色阳性呈棕褐色,多见于细胞质内,呈均匀或不均匀的颗粒状或团块状；随着肿瘤细胞增生活跃,阳性细胞数量增多,染色也增强。肿瘤组织中CD34均有表达,切片中肝癌血窦内皮细胞均见不同程度的黄染,癌旁可见个别血管染色。
结论：索拉非尼与TACE联合应用能够抑制肿瘤生长,并提高TACE治疗的疗效,通过应用多层螺旋CT灌注成像对肝VX2移植瘤血流灌注参数进行定量测定,以及与免疫组化进行对照研究,提示索拉非尼具有抗兔VX2肿瘤生长及抑制肿瘤血管生成的作用。
第四部分：索拉非尼治疗原发性肝癌的MSCT灌注与临床应用研究
目的：探讨MSCT灌注成像在评价索拉非尼治疗原发性肝癌中的临床价值。
方法：6名原发性肝癌患者在应用索拉非尼前与3个疗程后(3 months)行MSCT灌注及实验室常规检查,各项指标均进行统计学分析。
结果：原发性肝癌患者应用索拉非尼后,CT灌注参数HBF、HAF与PS显著下降(P<0.01)。其临床实验室常规检查(血常规、肝功能、肾功能)均无显著改变(P>0.05)。
结论：MSCT灌注成像可以评价索拉非尼治疗原发性肝癌的血液动力学变化。索拉非尼这种抗肿瘤药物临床副作用较小,是治疗原发性肝癌患者一个不错的选择。
Part one:Establishment of the rabbit VX2 liver tumor model and evaluation of the characteristics in different growth period on MSCT perfusion imaging
Purpose:To establish experimental rabbit VX2 liver model by implanting VX2 tumor cells into the rabbit liver, and to evaluate their perfusion parameter changes during different growth period.
Methods:The VX2 tumor was passaged through successive subcutaneous injection into the hind limb of the New Zealand white rabbits. Tumor cells were implanted in the left lobe of the rabbit liver (n=10). The MSCT perfusion scan was performed before and 7th day 14th day and 21th day after VX2 tumor cells implantation. The perfusion parametes including HBF, HBV, MTT, PS and HAF were measured in the tumor and non-tumorous regions. All the rabbits were executed for pathological examination after MSCT examnination at the third bearing-tumor week. The data were statistically analyzed.
Results:The rabbit VX2 liver tumor model was established successfully in this study. The tumors were demonstrated as low density with well-defined margin on the precontrast MSCT and were enhanced slightly on the postcontrast MSCT. The significant differences of the parameters of HBF, PS, HAF and HBV during the 1st-3rd week were found (P<0.01). There wre significant differences between the tumor area and non-tumorous area at the second week after tumor implantation The HBF, HBV, PS and HAF in the tumor area were increased after 2 weeks of tumor implantation and had stastistical differences as compared with non-tumorous area(P<0.01), while the MTT in the tumor area was decreased and had stastistical difference as compared with non-tumorous area(P<0.01). Ten solitary tumors, of which there was central cystic necrosis in 8 in pathological examination, were consistent with the imaging findings revealed by MSCT. Light microscope with low power revealed that the tumor was nest-like with newly-formed abundant capillary without clear margin between the tumor and liver parenchyma, and it revealed with high power that the tumor cells with abundant caryokinesis were bigger than those in normal liver cells, and they were distributed irregularly.
Conclusion:Tumor-implanting method was a satisfactory method in animal liver tumor model construction with easy-going, short-growing and high-successful and stabling features. MSCT perfusion imaging could well evaluate the hemodynamics changes of the rabbit liver VX2 tumor.. MSCT could provide more quantification information while combined with its histology examination.
Part two:Pre-and post-therapy of sorafenib for rabbit VX2 liver tumor:experimental study of neovascularization and cell apoptosis
Purpose:To study the changes of MSCT perfusion imaging parameters and histology of pre-and post-therapy of sorafenib for rabbit VX2 liver tumor. To explore the feasibility of MSCT perfusion imaging in monitoring neovascularization, and to provide experimental basis to evaluate the effect of sorafenib on the inhibition of tumor angiogenesis and promotion of tumor cell apoptosis.
Methods:The MSCT perfusion image was obtained in 12 New Zealand white rabbits at the second week after VX2 liver tumor implantation. Two of them were executed and served as the control group (for pathological examination), and the rest 10 rabbits were served as study group receiving oral administration of sorafenibat (20 m g/kg/d for one week) at 7-th day after tumor implantation. MSCT scans were performed respectively at 14-th and 21-th day after tumor implantation, and perfusion parameters (HBF, HBV, MTT, PS and HAF) in both groups were measured and compared in the tumor regions. Finally, all the rabbits were executed for Caspase-3 staining for detection of cell apoptosis.
Results:Twelve (100%) rabbits were successfully implanted with VX2 tumor in the liver. The values of HBF, PS and HAF in tumor of the two groups of MSCT perfusions images were significant different (P<0.01). There were no significant difference in HBV and MTT between the two groups (P> 0.05). The positive cells of the Caspase-3 were observed around central vein and necrosis area of hepatocyte. The intensity expression of the Caspase-3 in tumor tissue was significantly higher than that of normal control group (P<0.05).
Conclusion:MSCT combined with the histological examination could elucidate the therapeutic effects of sorafenib on the tumor angiogenesis inhibition and cell apoptosis promotion.
Part three:MSCT perfusion imaging and pathological study on rabbit VX2 liver tumor treated with combinaion therapy of transcatheter arterial chemoembolization(TACE) and sorafenib
Purpose:To study the changes of MSCT perfusion imaging and histology of rabbit VX2 liver tumor treated with combination therapy of TACE and sorafenib, and to explore the feasibility of improving the therapeutic effect of TACE by way of inhibition of tumor angiogenesis.
Methods:Licer tumor modle was establised in 30 New Zealand white rabbits. They were randomly divided into three groups based on therapy stratigies:(A) 0.9% Sodium Chloride group; (B) TACE group; (C) TACE Plus sorafenib group. The MSCT scan was performed at 1st week to 3th week after post-therapy in order to measure the volume changes of tumor. Tumor growing situations were observed by MSCT at pre-therapy and post-therapy (at the 1st,2nd and 3th week). MSCT perfusion parameters of HBF, HBV, MTT, PS and HAF in the tumor regions were measured at pre-theraspy and the 3th week of post-therapy. All the rabbits with VX2 tumor were executed for routine pathological examination and VEGF and CD34 staining after 3 weeks of treatment. Expression of VEGF and CD34 was detected, and the percentage of positive tumor cells and micro vessel density (MVD) were calculated and comapred at high power field (400×magnification).
Results:The size and growth rate of tumor were significant different between different groups. (P＜0.01). VEGF positive staining was mostly displayed homogeneous or inhomogeneous granule and clot with brown-yellow color in cytoplasm. The more tumor cells actively proliferated, the more abundant and strong staining positive tumor cells expressed. CD34 staining was expressed in tumor tissue, On light microscope, liver sinusoidal endothelial cells in the liver tissue were seen in varyied degrees of yellow dye. Individual vessel staining can be observed in adjacent cancer tissue.
Conclusion:Sorafenib could inhibit tumor angiogenesis and improve the therapeutic effect of the TACE. Measurement of MSCT perfusion parameters and comparson with liver tumor immunohistochemistry findings reflected that sonafenib could prevent tumor growth and inhibition of tumor angiogenesis.
Part four:Clinical application study of MSCT perfusion imaging in primary hepatic carcinomas treated with sorafenib
Purpose:To study the changes of MSCT perfusion parameter and clinical indexes on primary hepatic carcinomas treated with sorafenib and evaluate the therapeutic effect of sorafenib.
Methods:The MSCT perfusion and routine laboratory examination were performed on six patients with primary hepatic carcinomas before therapy and three months after treatment of sorafenib. All statistical data were done respectively.
Results:There was significant decrease in HBF, PS and HAF post-treatment with sorafenib (P＜0.01). There was no significant difference in blood test, hepatic function and renal function (P>0.05)
Conclusion:MSCT could evaluate the hemodynamic changes in patients with primary hepatic carcinomas after treatment with sorafenib. Sorafenb was the choice of treatment of primary hepatic carcinomas because of few side-effects.
目的：通过对兔肝脏种植VX2瘤株建立动物模型,为后续研究提供实验基础。并对该模型不同生长期的MSCT灌注参数进行研究,为MSCT灌注成像成为评价该肿瘤生长的影像学手段提供实验依据。
方法：10只新西兰大白兔,采用动物后肢皮下注射接种传代保存瘤种。然后采用开腹瘤块包埋法将其种植于兔肝左叶上。分别于种瘤前、种瘤后第1wk、2wk和第3wk行MSCT灌注扫描,对比种瘤前肝实质与种瘤后肿瘤区域以及第2wk肿瘤区与非肿瘤区肝脏的肝血流量(HBF)、肝血容积(HBV)、平均通过时间(MTT)、毛细血管表面通透性(PS)和肝动脉分数(HAF)的变化规律。种瘤后第3wk于CT检查完成后处死实验兔,进行肝脏病理学检查。所有结果均进行统计学分析。
结果：所有10只新西兰大白兔均成功建立了兔VX2肝种植瘤模型。瘤灶在CT平扫上表现为低密度,增强后病灶强化不明显,边界较清楚。肿瘤部位种瘤后1至3周HBF、PS、HAF、HBV值与种瘤前比较差异均有显著性意义(P<0.01)。种瘤后第2周,肿瘤区HBF、HBV、PS、HAF增高,与非肿瘤区肝组织比较差异有显著性意义(P<0.01)。肿瘤区MTT降低与非肿瘤区肝组织比较差异有显著性意义(P<0.01)。大体病理检查共发现10个单发肿瘤,其中8例中心出现坏死囊变区,与CT检查基本一致。光学低倍镜下见肿瘤细胞在肝内呈浸润性癌巢,与肝实质无明显边界,新生毛细血管丰富；高倍镜下可见瘤细胞体积大,呈不规则排列,核分裂像多见。
结论：采用瘤块种植制备的兔肝VX2肿瘤模型,同时具有容易制备、生长周期短、成功率高及模型稳定等特点,是一种较理想的肝肿瘤实验动物模型,是我们进行基础与临床研究很好的选择。MSCT灌注成像能较好地评价兔VX2肝种植瘤模型的血流动力学变化,结合组织学的研究则可以提供更多的量化信息。
第二部分兔VX2肝种植瘤索拉非尼治疗前、后的血管生成与细胞凋亡的实验研究
目的：通过对兔VX2肝种植瘤模型应用索拉非尼前后的CT灌注参数与组织学进行研究,探索应用CT灌注成像这种影像学手段来评价肿瘤新生血管生成的可行性,同时为索拉非尼抑制肿瘤血管生成并促进肿瘤细胞凋亡的临床效果提供实验依据。
方法：12只新西兰大白兔,采用开腹瘤块包埋法建立兔VX2肝种植瘤模型,2只建模后处死作为病理对照,其余10只于种瘤后第14d行多层螺旋CT灌注扫描,然后经口给予索拉非尼(20mg/kg/d) 7d,种瘤后第21d再次行CT检查,两次扫描肿瘤区所获得的参数值进行比较。检查完成后处死实验兔,进行细胞凋亡(Caspase-3)免疫组织化学染色。
结果：12只兔均接种成功。两次扫描肿瘤区所获得的参数HBF、PS和HAF值比较差异有显著性意义(P<0.01),HBV、MTT值差异无显著性意义。Caspase-3阳性细胞主要分布于中央静脉及肝细胞坏死灶周围。Caspase-3表达强度明显高于对照组(P<0.05)。
结论：CT灌注成像可以评价肿瘤新生血管的生成,而结合了组织学的研究则可以更加明确索拉非尼抑制肿瘤血管生成并促进肿瘤细胞凋亡的作用。
第三部分TACE联合索拉非尼治疗兔VX2肝种植瘤的MSCT灌注与病理及免疫组化对照研究
目的：通过对兔VX2肝种植瘤模型应用TACE联合索拉非尼前后的CT灌注参数与组织学进行研究,探讨通过应用抑制肿瘤血管生成药物以进一步提高TACE疗效方法的可行性。
方法：30只新西兰大白兔建立兔VX2肝种植瘤模型,将模型兔随机分成A、B、C三组,每组10只。A组为生理盐水对照组,B组为TACE治疗组,C组为TACE+索拉非尼联合治疗组。VX2肝种植瘤模型兔于治疗前(治疗时间选择接种VX2肿瘤组织2wk)及治疗后第1、2、3wk行CT平扫观察肿瘤生长情况。于治疗前与治疗后第3wk行CT灌注扫描并记录肿瘤的肝血流量(HBF)、肝血容积(HBV)、平均通过时间(MTT)、毛细血管表面通透性(PS)和肝动脉分数(HAF)等参数值。然后处死实验兔,进行病理以及血管内皮生长因子(vascular endothelial growth factor, VEGF)与CD34免疫组织化学染色。检测VEGF与CD34的表达情况,并在高倍视野下(×400)计算肿瘤细胞VEGF染色阳性率及微血管密度(micro vessel density, MVD)。
结果：治疗后不同时期各组两两比较肿瘤大小与肿瘤生长率均有显著性差异(P<0.01)。VEGF染色阳性呈棕褐色,多见于细胞质内,呈均匀或不均匀的颗粒状或团块状；随着肿瘤细胞增生活跃,阳性细胞数量增多,染色也增强。肿瘤组织中CD34均有表达,切片中肝癌血窦内皮细胞均见不同程度的黄染,癌旁可见个别血管染色。
结论：索拉非尼与TACE联合应用能够抑制肿瘤生长,并提高TACE治疗的疗效,通过应用多层螺旋CT灌注成像对肝VX2移植瘤血流灌注参数进行定量测定,以及与免疫组化进行对照研究,提示索拉非尼具有抗兔VX2肿瘤生长及抑制肿瘤血管生成的作用。
第四部分：索拉非尼治疗原发性肝癌的MSCT灌注与临床应用研究
目的：探讨MSCT灌注成像在评价索拉非尼治疗原发性肝癌中的临床价值。
方法：6名原发性肝癌患者在应用索拉非尼前与3个疗程后(3 months)行MSCT灌注及实验室常规检查,各项指标均进行统计学分析。
结果：原发性肝癌患者应用索拉非尼后,CT灌注参数HBF、HAF与PS显著下降(P<0.01)。其临床实验室常规检查(血常规、肝功能、肾功能)均无显著改变(P>0.05)。
结论：MSCT灌注成像可以评价索拉非尼治疗原发性肝癌的血液动力学变化。索拉非尼这种抗肿瘤药物临床副作用较小,是治疗原发性肝癌患者一个不错的选择。
Part one:Establishment of the rabbit VX2 liver tumor model and evaluation of the characteristics in different growth period on MSCT perfusion imaging
Purpose:To establish experimental rabbit VX2 liver model by implanting VX2 tumor cells into the rabbit liver, and to evaluate their perfusion parameter changes during different growth period.
Methods:The VX2 tumor was passaged through successive subcutaneous injection into the hind limb of the New Zealand white rabbits. Tumor cells were implanted in the left lobe of the rabbit liver (n=10). The MSCT perfusion scan was performed before and 7th day 14th day and 21th day after VX2 tumor cells implantation. The perfusion parametes including HBF, HBV, MTT, PS and HAF were measured in the tumor and non-tumorous regions. All the rabbits were executed for pathological examination after MSCT examnination at the third bearing-tumor week. The data were statistically analyzed.
Results:The rabbit VX2 liver tumor model was established successfully in this study. The tumors were demonstrated as low density with well-defined margin on the precontrast MSCT and were enhanced slightly on the postcontrast MSCT. The significant differences of the parameters of HBF, PS, HAF and HBV during the 1st-3rd week were found (P<0.01). There wre significant differences between the tumor area and non-tumorous area at the second week after tumor implantation The HBF, HBV, PS and HAF in the tumor area were increased after 2 weeks of tumor implantation and had stastistical differences as compared with non-tumorous area(P<0.01), while the MTT in the tumor area was decreased and had stastistical difference as compared with non-tumorous area(P<0.01). Ten solitary tumors, of which there was central cystic necrosis in 8 in pathological examination, were consistent with the imaging findings revealed by MSCT. Light microscope with low power revealed that the tumor was nest-like with newly-formed abundant capillary without clear margin between the tumor and liver parenchyma, and it revealed with high power that the tumor cells with abundant caryokinesis were bigger than those in normal liver cells, and they were distributed irregularly.
Conclusion:Tumor-implanting method was a satisfactory method in animal liver tumor model construction with easy-going, short-growing and high-successful and stabling features. MSCT perfusion imaging could well evaluate the hemodynamics changes of the rabbit liver VX2 tumor.. MSCT could provide more quantification information while combined with its histology examination.
Part two:Pre-and post-therapy of sorafenib for rabbit VX2 liver tumor:experimental study of neovascularization and cell apoptosis
Purpose:To study the changes of MSCT perfusion imaging parameters and histology of pre-and post-therapy of sorafenib for rabbit VX2 liver tumor. To explore the feasibility of MSCT perfusion imaging in monitoring neovascularization, and to provide experimental basis to evaluate the effect of sorafenib on the inhibition of tumor angiogenesis and promotion of tumor cell apoptosis.
Methods:The MSCT perfusion image was obtained in 12 New Zealand white rabbits at the second week after VX2 liver tumor implantation. Two of them were executed and served as the control group (for pathological examination), and the rest 10 rabbits were served as study group receiving oral administration of sorafenibat (20 m g/kg/d for one week) at 7-th day after tumor implantation. MSCT scans were performed respectively at 14-th and 21-th day after tumor implantation, and perfusion parameters (HBF, HBV, MTT, PS and HAF) in both groups were measured and compared in the tumor regions. Finally, all the rabbits were executed for Caspase-3 staining for detection of cell apoptosis.
Results:Twelve (100%) rabbits were successfully implanted with VX2 tumor in the liver. The values of HBF, PS and HAF in tumor of the two groups of MSCT perfusions images were significant different (P<0.01). There were no significant difference in HBV and MTT between the two groups (P> 0.05). The positive cells of the Caspase-3 were observed around central vein and necrosis area of hepatocyte. The intensity expression of the Caspase-3 in tumor tissue was significantly higher than that of normal control group (P<0.05).
Conclusion:MSCT combined with the histological examination could elucidate the therapeutic effects of sorafenib on the tumor angiogenesis inhibition and cell apoptosis promotion.
Part three:MSCT perfusion imaging and pathological study on rabbit VX2 liver tumor treated with combinaion therapy of transcatheter arterial chemoembolization(TACE) and sorafenib
Purpose:To study the changes of MSCT perfusion imaging and histology of rabbit VX2 liver tumor treated with combination therapy of TACE and sorafenib, and to explore the feasibility of improving the therapeutic effect of TACE by way of inhibition of tumor angiogenesis.
Methods:Licer tumor modle was establised in 30 New Zealand white rabbits. They were randomly divided into three groups based on therapy stratigies:(A) 0.9% Sodium Chloride group; (B) TACE group; (C) TACE Plus sorafenib group. The MSCT scan was performed at 1st week to 3th week after post-therapy in order to measure the volume changes of tumor. Tumor growing situations were observed by MSCT at pre-therapy and post-therapy (at the 1st,2nd and 3th week). MSCT perfusion parameters of HBF, HBV, MTT, PS and HAF in the tumor regions were measured at pre-theraspy and the 3th week of post-therapy. All the rabbits with VX2 tumor were executed for routine pathological examination and VEGF and CD34 staining after 3 weeks of treatment. Expression of VEGF and CD34 was detected, and the percentage of positive tumor cells and micro vessel density (MVD) were calculated and comapred at high power field (400×magnification).
Results:The size and growth rate of tumor were significant different between different groups. (P＜0.01). VEGF positive staining was mostly displayed homogeneous or inhomogeneous granule and clot with brown-yellow color in cytoplasm. The more tumor cells actively proliferated, the more abundant and strong staining positive tumor cells expressed. CD34 staining was expressed in tumor tissue, On light microscope, liver sinusoidal endothelial cells in the liver tissue were seen in varyied degrees of yellow dye. Individual vessel staining can be observed in adjacent cancer tissue.
Conclusion:Sorafenib could inhibit tumor angiogenesis and improve the therapeutic effect of the TACE. Measurement of MSCT perfusion parameters and comparson with liver tumor immunohistochemistry findings reflected that sonafenib could prevent tumor growth and inhibition of tumor angiogenesis.
Part four:Clinical application study of MSCT perfusion imaging in primary hepatic carcinomas treated with sorafenib
Purpose:To study the changes of MSCT perfusion parameter and clinical indexes on primary hepatic carcinomas treated with sorafenib and evaluate the therapeutic effect of sorafenib.
Methods:The MSCT perfusion and routine laboratory examination were performed on six patients with primary hepatic carcinomas before therapy and three months after treatment of sorafenib. All statistical data were done respectively.
Results:There was significant decrease in HBF, PS and HAF post-treatment with sorafenib (P＜0.01). There was no significant difference in blood test, hepatic function and renal function (P>0.05)
Conclusion:MSCT could evaluate the hemodynamic changes in patients with primary hepatic carcinomas after treatment with sorafenib. Sorafenb was the choice of treatment of primary hepatic carcinomas because of few side-effects.
引文
[1]Tsushima Y, Funabasama S, Aoki J, et al. Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data[J]. Acad Radiol,2004,11(2):215-223.
[2]Komemushi A, Tanigawa N, Kojima H, et al. CT perfusion of the liver during selective hepatic arteriography:Pure arterial blood perfusion of liver tumor and parenchyma[J]. Radiat Med,2003,21(6):246-251.
[3]Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumor[J]. Phys Med Biol.2001,46 (12):3161-3175.
[4]Moroz P, Jones SK, Winter J, et al. Targeting liver tumors with hyper thermia:Ferromagnetic embolization in rabbit liver tumor model[J]. Surg Res, 2001,99(2):265-271.
[5]Yoon CJ, Chung JW, Park JH, et al. Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor [J]. Radiology,2003, 229(1):126-131.
[6]Hong K, Kobeiter H, Georgiades CS, et.al. Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer[J]. J Vasc Interv Radiol,2005,16 (12):1711-1717.
[7]柳曦,李欣,赵俊功,等.兔VX2肝癌模型制作及综合影像评价[J].实用放射学杂志,2002,18(2)：132-134.
[8]张琳,丁仕义,黄学全.兔VX2肝转移癌模型传代的改进和螺旋CT评价[J].第三军医大学学报,2002,24(9)：1125-1127.
[9]万智勇,冯敢生,余宏建.兔移植性肝癌伴门静脉癌栓模型的制作[J].临床放射学杂志,2003,22(6)：517-519.
[10]Kapanen MK, Halavaara JT, Hakkinen AM. Assessment of vascular physiology of tumorous livers:comparison of two different methods[J]. Acad Radiol,2003, 10(9):1021-1029.
[11]邵国良,周康荣,王建华,等.介入治疗实验研究中兔VX2肝癌模型制作的改进和CT评价[J].临床放射学杂志,2000,19(10)：653-654.
[12]贾洪顺,全显跃,曾盛,等.兔VX2肝癌CT、MRI动态评价[J].第一军医大学学报,2002,22(2)：141-144.
[13]Kuszyk BS, Bluemke DA, Choti MA, et al. Contrast-enhaneed CTof small hypovascular hepatic tumor:effect of lesion enhancement on conspicuity in rabbits[J].AIR,2000,174(2):471-475.
[14]吴安乐,颜志平,周康荣,等.兔VX2瘤转移性肺癌动物模型的建立和生物学特性研究[J].中华放射学杂志,2003,37(2)：166170.
[15]Maruyama H,Matsutani S, Saisho H, et al. Sonographic shift of hypervascular liver tumor on blood pool harmonic images with definity:time-related changesof contrast—enhanced appearance in rabbit VX2 tumor under extra-low acoustic power[J].Eur J Radiol,2005;56(1):60-65.
[16]Kim YI, Chung JW, Park JH, et al. Intraarterial gene delivey in rabbit hepatic tumors:transfection with nonviral vector by using iodized oil emulsion[J].Radiology,2006;240(3):771-777.
[17]Burgener FA, Violante MR.Comparison of hepatic VX2-carcinomas after intra-arterial, intraportal and intraparenchymal tumor cell injection. An angiographic and computed tomographic study in the rabbit[J]. Invest Radiol, 1979,14(5):410-414.
[18]Mitsumori M, Hiraoka M, ShibataT, et al. Targeted hyperthermia using dextran magnetite complex:a new treatment modality for liver tumors [J].Hepatogastroenterology,1996:43(12):1431-143.
[19]Terayama N, Terada T, Nakanuma Y. A morphometric and immunohlstochemical study on angiogenesis of human metastatic carcinomas of the liver[J]. Hepatology, 1996,24(4):816-819.
[20]Gervaz P, Scholl B, Mainguene C, et al. Angiogenesis of liver metastases: role of sinusoidal endothelial cells[J]. Dis Colon Rec turn,2000,43(7):980-986.
[21]Paku S, Lapis K. Morphological aspects of angiogenesis in experimental liver metastases[J]. Am J Pathol,1993,143(3):926-936.
[22]Terayama N, Terada T, Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue [J]. Histopathology, 1996,29(1):37-43.
[23]Blomley MJ, Coulden R, Dawson P, et al. Liver Perfusion studied with Ultrafast CT[J]. J Comput Assist Tomogr,1995,19(3):424-433.
[24]Komemushi A, Tanigawa N, Kojima H, et al. CT Perfusion of the liver during selective hepatic arteriography:Pure arterial blood Perfusion of liver tumor and Parenchyma[J]. Radiat Med,2003,21(6):246-251.
[25]Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumor [J]. Phys Med Biol,2001,46(12):3161-3175.
[26]Cenie A, Nabavi DG,Craen RA, et al. Dynamic CT measurement of cerebral blood flow:a validation study[J]. AJNR Am J Neuroradiol,1999;20(1):63-68.
[27]王爽,赵心明,林蒙,等.原发性肝脏肿瘤的CT灌注研究[J].中国医学影像技术,2006,22(1)：95-98.
[28]文利,丁仕义,周代全等.正常肝脏CT灌注的研究[J].第三军医大学学报,2002,24(6)：943-947.
[29]时高峰,王琦,许茜,等.大鼠Walker-256肝微小转移癌模型的CT灌注成像研究[J].中国医学影像技术,2006,22(1)：35-38.
[30]Zhang J, Wang R, Wang M, et al. Experimental study of multi-slice spiral CT Perfusion imaging in VX2 soft-tissue tumor of rabbits[J]. J Huazhong Univ Sci Technolog.Med Sci,2006,26(3):341-343.
[31]Kapanen MK, Halavaara JT, Hakkinen AM. Assessment of vascular physiology of tumorous livers:comparison of two different methods[J]. Acad Radiol, 2003,10(9):1021-1029.
[1]Folkman J. Angiogenesis and breast caneer[J].J Clin oncol,1994,12(3):441-448.
[2]Blood CH, Zetter BR. Thmor interactions with vasculature angiogenesis and tumnor metastasis[J].Biochem Biophys Acta,1990,1032(1):89-95.
[3]Dezso K, Bugyik E, Papp V,et al.Development of arterial blood supply in experimental liver [J]. Am J Pathol.2009,175(2):835-843.
[4]Zhang N, Wang L, Liang Y,et al.The antiangiogenic effects of tyroservatide on animal models of hePatocellular carcinoma[J].J Cancer Res Clin Oncol. 2009,135(10):1447-1453.
[5]Folkman J.Tumor angiogenesis therapeutic implications [J]. New Engl J Med, 1971,285(12):1182-1189.
[6]Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotie cell death[J]. Cell Death Differ,1999; 6(11):1028-1031
[7]Varghese J, Chattopadhaya S, Sarin A. Inhibition of p38 kinase reveals a TNF2α2 mediated, caspase dependent, apoptotic death pathway in a human myelomonocyte cell line[J]. J Immunol,2001; 166(11):6570-6577.
[8]林春龙,张珍祥.FAK反义寡核苷酸促进人肺动脉平滑肌细胞凋亡[J].中国病理生理杂志,2006,22(2)：288-293.
[9]LIovet JM, Bruix J. Sorafenib in advanced hepatocellular carcinoma [J].N Engl J Med,2008,359(2):378-390.
[10]秦叔逵,龚新雷.索拉非尼治疗原发性肝癌的研究进展[J].临床肿瘤学杂志,2008,13(12)：1057-1068.
[1]张成武,赵大建,胡智明,等。原发性肝癌经肝动脉栓塞化疗术后预后指标的多因素分析[J]。肝胆胰外科杂志,2007,19(6)：376-379.
[2]吴孟超.原发性肝癌外科综合治疗的现状和展望[J].。中华外科杂志,2004,42(1)：13-15.
[3]Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery[J]. Ann Surg Oncol,2003,10: 355-362.
[4]Liao XF, Yi JL, Li XR, et al. Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization[J]. World J Gastroenterol.2004,10(13): 1885-1889.
[5]Vamesu S. Angiogenesis and tumor grading in primary breast cancer patients:analysis of 158 needle core biopsies[J]. Rom J MorPhol Embryol, 2006,47(3):251-257.
[6]Weidner N.Current Pathologic methods for measuring intratumoral microvessel density with breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-180.
[7]Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion[J]. Cancer,1991,67(3):385-391.
[8]Maio ED, Fiore F, Daniele B, et al. Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma:a review of literature[J]. Critical Reviews in Oncology/Hematology,2003,46(2):285-295.
[9]Maki S, Konno T,Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium[J]. Cancer,1985,56(3):751-757.
[10]崔俊,韩铭钧,杨冬华,等。碘油CT对肝癌诊断及疗效判断的价值[J]。世界华人消化杂志,2000,8(6)：837-839.
[11]Bartolozzi C, Lencioni R,Caramella D,et al.Hepatocellular carcinoma:CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection[J]. Radiology,1994,191(1):123-128.
[12]肖运平,肖恩华,罗建光,等。MR弥散成像在肝细胞癌经导管动脉化疗栓塞术后疗效评价中的价值[J]。中国医学影像技术,2008,24(2)：270-273.
[13]Van Beers BE, Lecote I,Materne R,et al. Hepatic perfusion parameters in chronic liver disease:dynamic CT measurements correlated with disease severity[J].AJR,2001,176(4):667-673.
[14]王爽,赵心明,林蒙,等。肝脏CT灌注成像在肝癌早期诊断中的价值[J]。放射学实践,2008,23(2)：200-284.
[15]Taushima Y, Funabasama S,Aoki J,et al.Quantitative perfusion map of malignant liver tumors,created from dynamic computed tomography data [J].Acad Radiol,2004,11(2):215-223.
[16]Kim YB, Park YN, Park C. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization[J]. Histopathology,2001,38(2): 160-166.
[17]郭吉刚,郭顺林,杜富会,等.原发性肝癌TACE治疗前后血清VEGF含量的变化[J].中国临床医学影像杂志,2003,14(3)：181-183.
[18]Kim KW, Bae SK, Lee OH, et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma[J]. Cancer Res,1998,58(4):348-351.
[19]Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma:a prospective study [J]. J Clin Oncol,2002,20(14):1775-1785.
[20]Borgstrom P, Hillan K, Sriramaro P, et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody[J]. Cancer Res,1996,56(21):4032-4039.
[21]Huang J, He X, Lin X, et al. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma[J]. Chin Med J,2000,113(5):446-448.
[22]Ren B, Hoti N, Rabasseda X, et al. The antiangiogenic and therapeutic implications of endostatin[J]. Methods Find ExP Clin Pharmacol 2003,25(2): 215-224.
[23]Cao Y, Cao R, Veitonmaki N. Kringle structures and antiangiogenesis[J]. Curr Med Chem Anticancer Agents 2002,2(3):667-681.
[24]Kuwahara K, Sasaki T, Kuwada Y, et al. Expressions of angiogenic factors in Pancreatic ductal carcinoma:a correlative study with clinicopathologic parameters and patient survival[J]. Pancreas,2003,26(4):344-349.
[25]Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J]. Nature, 2000,407(2):249-257.
[26]Ho QT, Kuo CJ. Vascular endothelial growth factor:Biology and therapeutic applications[J]. Int J Biochem & Cell Biol,2007,39(8):1349-1357.
[27]Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer[J]. Hum Pathol,1995,26(1):86-91.
[28]Pak YN, Kin YB, Yang KM, et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis[J]. Arch Pattol Lab Med,2000,124 (7):1061-1065.
[29]Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A,1998,95 (36):15809-15814.
[30]CamP ER, Yang A, Liu WB, et al. Combined anti-vascular effects of VEGFR-2 blockade and inhibition of nitric oxide[J]. J Am Coll Surgeons,2005,201(3): 82-87.
[31]Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors[J]. Cancer Cell,2005,8(3):299-309.
[32]Cheung AMY, Brown AS, Cucevic V, et al. Detecting Vascular Changes in Tumour Xenografts Using Micro-Ultrasound and Micro-CT Following Treatment with VEGFR-2 Blocking Antibodies [J]. Ultrasound in Med & Biol. 2007,33(8):1259-1268.
[33]柏斗胜,钱海鑫,秦磊,等.血管形成抑制剂TNPO470对小鼠肝癌术后复发和转移防治的研究[J].实用临床医药杂志,2004,8(1)：45-46.
[34]Drixler TA, Rinkes IH, Ritchie ED, et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy[J]. Cancer Res,2000,60 (16):1761-1765.
[35]Abdollahi A, Hlatky L b, Peter EH. Endostatin:The logic of antiangiogenic therapy[J]. Drug Resistance Updates,2005,8(1):59-74.
[36]Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1[J]. J Biol Chem,2002,277 (19):16464-16469.
[1]陈光斌,邹文远,李金科,等.螺旋CT灌注成像评价肝细胞癌TACE术后活性灶血供[J].郧阳医学院学报,2007,26(4)：206-209.
[2]聂永康,蔡祖龙.毛细血管灌注及通透性的CT测量及其临床应用[J].中国医学影像学杂志,2001,9(3)：211-218.
[3]Van BE, Leconte I, Materne R, et al. Hepatic perfusion parameters in chronic liver disease dynamic CT measurements correlated with disease severity[J]. AJR Am J Roentgenol,2001,176 (3):667-673.
[4]Leen E, Goldberg JA, Angerson MJ,et al. Potential role of Doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy [J].Lancet,2000,355(9197):34-37.
[5]Padhani AR.Dynamic contrast-enhanced MRI studies in human tumours[J].BrJ Radiol,1999,72(857):427-431.
[6]Hulka CA, Edmister WB, Snuth BL, et al.Dynamic echo-planar imaging of the breast:experience in diagnosing breast carcinoma and correlation with tumor angiogenesis[J].Radiology,1997,205(3):837-842.
[7]RazaS,Baum JK.Solid breast lesions:evaluation with power Doppler US [J].Radiology,1997,203(1):164-168.
[8]Blomley MJ, Lim AK, Harvey CJ, etal. Liver microbubble transit time Compared with histology and Child-Pugh score in diffuse liver disease:a cross sectional study[J].Gut,2003,52(8):1188-1193.
[9]Miles KA.Tumour angiogenesis and its relation to contrast enhancement on computed tomography:a review[J].Eur J Radiol,1999,30(3):198-205.
[10]Hirata M, Sugawara Y, Murase K, et al. Evaluation of optimal scan duration and end time in cerebral CT perfusionstudy[J].Radiat Med,2005,23(5):351-363.
[11]Miles KA.Measurement of tissue perfusion by dynamic computed tomography [J].Br J Radiol,1991,4(761):409-412.
[12]Miles KA, Hayball M, Dixon AK.Colour perfusion imaging:a new application of computed tomography [J].Laneet,1991,337(8742):643-645.
[13]Miles KA, Hayball MP, Dixon AK.Functional images of hepatic perfusion obtained with dynamic CT[J].Radiology,1993,188(2):405-411.
[14]Miles KA, Hayball MP, Dixon AK. Measurement of human pancreatic perfusion usingd dynamic computed tomography ywith perfusion imaging[J]. Br J Radiol,1995,68(809):471-475.
[15]Terayama N, Terada T, Nakanuma Y. A morphometric and immunohlstochemical study on angiogenesis of human metastatic carcinomas of the liver[J]. Hepatology,1996, 24(4):816-819.
[16]Gervaz P, Scholl B, Mainguene C, et al. Angiogenesis of liver metastases: role of sinusoidal endothelial cells[J]. Dis Colon Rec turn,2000,43(7): 980-986.
[17]Paku S, Lapis K. Morphological aspects of angiogenesis in experimental liver metastases[J]. Am J Pathol,1993,143(3):926-936.
[18]Terayama N, Terada T, Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue [J]. Histopathology, 1996,29(1):37-43.
[19]王爽,赵心明,林蒙,等.原发性肝脏肿瘤的CT灌注研究[J].中国医学影像技术,2006,22(1)：95-98.
[20]文利,丁仕义,周代全等.正常肝脏CT灌注的研究[J].第三军医大学学报,2002,24(6)：943-947.
[21]Li Z,Huang, Li S,et al.Blood supply of liver metastasis[J]. Beijing Da Xue Xue Bao,2008,40(2),146-150.
[22]Meijerink MR,Waesberghe JH,Weide L. Total-liver-volume perfusion CT using 3D image for fusion to improve detection and characterization of liver metastases[J]. Eur Radiol,2008,18(10):2345-2354.
[23]Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment[J]. Drugs Today(Barc),2005,41(12): 773-784.
[24]Beeram M, Patnaik A, Rowlnsky EK. Regulation of c-Raf—1:therapeutic implications[J]. Clin Adv Hematol Oncol,2003,1(8):476-481.
[25]Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol,2006, 24(26):4293-4297.
[26]Ratain MJ, Eisen T, Stadler WM, et al.Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2006,24(16):2505-2511.
[27]Patel PH, Chaganti RS,Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer,2006,94(5):614-619.
[28]Bleumer I, Knuth A, Osterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma paients[J]. Br J Cancer.2004,90(5):985-992.
[29]Veronese ML, Mosenkis A, Flaberty KT, et al. Mechanisms of hypertension associated with BAY 43-9006[J]. J Clin Oncol,2006,24(9):1363-1369.
[30]Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma[J]. New Engl J Med,2008,359(4):378-390.
[1]Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumorcell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res,2006,66(24): 11851-11858.
[2]伍婧,罗荣城,张华,等.索拉非尼联合三氧化二砷对肝癌细胞株的抑制作用[J].南方医科大学学报,2008,28(4)：639-641.
[3]陈逢生,崔彦芝,罗荣城,等.索拉非尼联合顺铂抑制肝癌HepG2细胞生长的体外研究[J].南方医科大学学报,2008,28(9)：1684-1687.
[4]Wang Z, Zhou J, Fan J, etal. Effect of rapamycinalone andin combination with sorafenib in all orthotopic model of human hepatocellularcarcinoma[J]. Clin Cancer Res,2008,14(16):5124-5130.
[5]Strumberg D, Richly H, Hilger RA, et al. Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patientswith advanced refractory solid tumors[J]. Journal of Clinical Oncology,2005,23(5):965-972.
[6]Clark JW, Eder JP, Ryan D, et al. Safety and pharmaeokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors[J]. Clin Cancer Res,2005,11(15):5472-5480.
[7]Awada A, Hendlisz A, Gil T, et al. Phase Ⅰ safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors[J]. Br J Cancer,2005,92(10):1855-1861.
[8]Moore M, Hirte HW, Siu L, et al. Phase Ⅰ study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 439006, administered for 28 days on/7days off in patients with advanced, refractory solid tumors[J]. Ann Oncol,2005,16(10):1688-1694.
[9]Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma[J]. Cancer Sci,2008,99(1):159-165.
[10]Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma[J]. Journal of Clinical Oncology,2006,24(26):4293-4300.
[11]Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced Hepatocellular Carcinoma[J]. N Engl J Med,2008,359(4):378-390.
[12]Richly H, Henning BF, Kupsch P, et al. Results of a Phase Ⅰ trial of sorafenib(BAY 430006)in combination with doxorubicin in patients with refractory solid tumom[J]. Ann Oncol,2006,17(5):866-873.
[13]Abou-Alfa G, Johnson P, Knox J, et al. Preliminary results from a Phase Ⅱ, randomized, double-blind study of sorafenib plus doxornbiein versus placebo plus doxornbiein in patients with advanced hepatoeellular carcinoma [J]. European Journal of Cancer,2007,5(Suppl):a 3500.
[14]Abou-Alfa G, Johnson P, Knox J, et al. Sorafenib plus doxornbiein may offer better time to progression than doxornbiein alone in advanced International Congress on Anti-Cancer Treatment(ICACT),2008 [2008-11-12].
[15]隋忠国,薛宏伟,荆凡波,等.索拉非尼联合卡培他滨治疗肝细胞癌患者的临床研究[J].中国药房,2008,19(11)：848-849.
[1]Sahani DV, Holalkere NS, Mueller PR,et al. Advanced Hepatocellular Carcinoma:CT Perfusion of Liver and Tumor Tissue—Initial Experience. Radiology.2007,243(3):736-743.
[2]Cha C, DeMatteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Practice & Research Clinical Gastroenterology,2005,19(1): 25-37.
[3]钦伦秀,孙惠川,汤钊猷.原发性肝癌研究进展——2006沪港国际肝病大会纪要.中华外科杂志,2006,44(15)：1070-1074.
[4]Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991,67(4):385-391.
[5]Maio, ED, Fiore, F, Daniele,B, et al. Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma:a review of literature. Critical Reviews in Oncology/Hematology.2003,46(2),285-295.
[6]张成武,赵大建,胡智明,等.原发性肝癌经肝动脉栓塞化疗术后预后指标的多因素分析.肝胆胰外科杂志,2007,19(6)：376-379.
[7]吴孟超.原发性肝癌外科综合治疗的现状和展望.中华外科杂志,2004,42(1)：13-15.
[8]Kim YB, Park YN, Park C. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology,2001,38(3): 160-166.
[9]郭吉刚,郭顺林,杜富会,等.原发性肝癌TACE治疗前后血清VEGF含量的变化.中国临床医学影像杂志,2003,14(3)：181-183.
[10]Kim KW, Bae SK, Lee OH, et al. Insulin-like growth factor Ⅱ induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res,1998,58(4):348-351.
[11]Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma:a prospective study. J Clin Oncol,2002,20(5):1775-1785.
[12]Borgstrom P, Hillan K, Sriramaro P, et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody. Cancer Res,1996,56(6):4032-4039.
[13]Huang J, He X, Lin X, et al. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma. Chin Med J,2000,113(5):446-448.
[14]Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol,2003,10(3): 355-362.
[15]Liao XF, Yi JL, Li XR, et al. Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol.2004,10(13): 1885-1889.
[16]Folkman J. Tumour angiogenesis:a possible control point in tumor growth. Ann Intern Med 1975; 82(1):96-100.
[17]廖晓锋,易继林,张伟杰,等.兔肝癌肝动脉栓塞后肿瘤血管生成的变化.中华实验外科杂志,2004,21(10)：1173-1175.
[18]Folkman J, Shing Y. Angiogensesis. J Biol Chem,1992,267(16):10931-10934
[19]Conti CJ. Vascular endothelial growth factor:regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. Oncologist 2002,7(Suppl3):4-11.
[20]Bandoh N, Hayashi T, Takahara M, et al. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis. Cancer Lett 2004,208(2): 215-225.
[21]Ren B, Hoti N, Rabasseda X, et al. The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol 2003; 25: 215-224
[22]Cao Y, Cao R, Veitonmaki N. Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents 2002,2(4):667-681.
[23]Kuwahara K, Sasaki T, Kuwada Y, et al. Expressions of angiogenic factors in pancreatic ductal carcinoma:a correlative study with clinicopathologic parameters and patient survival. Pancreas 2003,26(3):344-349.
[24]Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature,2000, 407(3):249-257.
[25]Ho QT, Kuo CJ. Vascular endothelial growth factor:Biology and therapeutic applications. Int J Biochem & Cell Biol,2007(39):1349-1357.
[26]Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol,1995,26(1):86-91.
[27]Pak YN, Kin YB, Yang KM, et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pattol Lab Med,2000,124 (7):1061-1065.
[28]Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A,1998,95(18):15809-15814.
[29]Hanahan D, Folkman J. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis. Cell,1996,86(3):353-364.
[30]Camp ER, Yang A, Liu WB, et al. Combined anti-vascular effects of VEGFR-2 blockade and inhibition of nitric oxide. J Am Coll Surgeons,2005,201(3): 82-91.
[31]Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell,2005,8(3):299-309.
[32]Cheung AMY, Brown AS, Cucevic V, et al. Detecting Vascular Changes in Tumour Xenografts Using Micro-Ultrasound and Micro-CT Following Treatment with VEGFR-2 Blocking Antibodies. Ultrasound in Med & Biol. 2007,33(8):1259-1268.
[33]柏斗胜,钱海鑫,秦磊,等.血管形成抑制剂TNPO470对小鼠肝癌术后复发和转移防治的研究.实用临床医药杂志,2004,8(1)：45-46.
[34]Drixler TA, Rinkes IH, Ritchie ED, et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res,2000,60 (16):1761-1765.
[35]Abdollahi A, Hlatky L b, Peter EH. Endostatin:The logic of antiangiogenic therapy. Drug Resistance Updates,2005,8(1):59-74.
[36]Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem,2002,277 (19): 16464-16469.
[37]Sophie JB, Melissa RS, Joel MR, et al. Pharmacokinetics of Intravitreal Bevacizumab (Avastin). Ophthalmology,2007,114(9):855-859.
[38]Sophie JB, Melissa RS, Joel MR, et al. Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). Ophthalmology 2007,114(13):2179-2182.
[39]Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006,26(5):495-511.
[40]Abdollahi A, Hlatky L b, Peter EH. Endostatin:The logic of antiangiogenic therapy. Drug Resistance Updates,2005,8(1):59-74.
[41]Czito GB, Bendell JC, Willett CG Bevacizumab, Oxaliplatin, and Capecitabine With Radiation Therapy in Rectal Cancer:Phase I Trial Results. Int J Radiat oncol,2007,68(2):472-478.
[42]Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography:a review. Eur J Radiol,1999,30 (3):198-205.
[43]Tsushima Y, Funabasama S, Aoki J, et al. Quantitative Perfusion Map of Malignant Liver Tumors, Created From Dynamic Computed Tomography Datal. Academic Radiology,2004,11(2):215-223.
[44]陈光斌,邹文远,李金科,等.螺旋CT灌注成像评价肝细胞癌TACE术后 活性灶血供.郧阳医学院学报,2007,26(4)：206-209.
[45]聂永康,蔡祖龙.毛细血管灌注及通透性的CT测量及其临床应用.中国医学影像学杂志,2001,9(3)：211-218.
[46]Van BE, Leconte I, Materne R, et al. Hepatic perfusion parameters in chronic liver disease dynamic CT measurements correlated with disease severity. AJR Am J Roentgenol,2001,176 (3):667-673.
[47]肖恩华,胡国栋,李锦清,等.肝细胞癌化疗栓塞方法和肿瘤坏死.临床放射学杂志,2000,19(8)：513-515.
[48]Yamada N, Imakita S, Sakuma T, et al. Intracranial calcificationon gradient echo phase images:depiction of diam agnetic susceptibility. Radiology,1996, 198(1):171-178.
[49]Sehgal V, Delproposto Z, HaackeEM, et al.Clinical applications of neuroimaging with susceptibility weighted imaging[J]. J Magn Reson imaging,2005,22(3):439-450.
[50]Sehgal V, Delproposto Z, Haddar D, et al. Susceptibility weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses[J]. J Magn Reson Imaging,2006,24(1):41-51.
[51]刘亚欧,杨延辉,李坤成.磁敏感加权成像在中枢神经系统的临床应用[J].医学影像学杂志,2007,17(2)：210-212.
[52]Takeuchi M, Matsuzaki K, Nishitani H. Susceptibility-weighted MRI of endometrioma:Preliminary results[J].AJR Am Roentqenol,2008,191 (5):1366-1370.
[2]Komemushi A, Tanigawa N, Kojima H, et al. CT perfusion of the liver during selective hepatic arteriography:Pure arterial blood perfusion of liver tumor and parenchyma[J]. Radiat Med,2003,21(6):246-251.
[3]Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumor[J]. Phys Med Biol.2001,46 (12):3161-3175.
[4]Moroz P, Jones SK, Winter J, et al. Targeting liver tumors with hyper thermia:Ferromagnetic embolization in rabbit liver tumor model[J]. Surg Res, 2001,99(2):265-271.
[5]Yoon CJ, Chung JW, Park JH, et al. Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor [J]. Radiology,2003, 229(1):126-131.
[6]Hong K, Kobeiter H, Georgiades CS, et.al. Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer[J]. J Vasc Interv Radiol,2005,16 (12):1711-1717.
[7]柳曦,李欣,赵俊功,等.兔VX2肝癌模型制作及综合影像评价[J].实用放射学杂志,2002,18(2)：132-134.
[8]张琳,丁仕义,黄学全.兔VX2肝转移癌模型传代的改进和螺旋CT评价[J].第三军医大学学报,2002,24(9)：1125-1127.
[9]万智勇,冯敢生,余宏建.兔移植性肝癌伴门静脉癌栓模型的制作[J].临床放射学杂志,2003,22(6)：517-519.
[10]Kapanen MK, Halavaara JT, Hakkinen AM. Assessment of vascular physiology of tumorous livers:comparison of two different methods[J]. Acad Radiol,2003, 10(9):1021-1029.
[11]邵国良,周康荣,王建华,等.介入治疗实验研究中兔VX2肝癌模型制作的改进和CT评价[J].临床放射学杂志,2000,19(10)：653-654.
[12]贾洪顺,全显跃,曾盛,等.兔VX2肝癌CT、MRI动态评价[J].第一军医大学学报,2002,22(2)：141-144.
[13]Kuszyk BS, Bluemke DA, Choti MA, et al. Contrast-enhaneed CTof small hypovascular hepatic tumor:effect of lesion enhancement on conspicuity in rabbits[J].AIR,2000,174(2):471-475.
[14]吴安乐,颜志平,周康荣,等.兔VX2瘤转移性肺癌动物模型的建立和生物学特性研究[J].中华放射学杂志,2003,37(2)：166170.
[15]Maruyama H,Matsutani S, Saisho H, et al. Sonographic shift of hypervascular liver tumor on blood pool harmonic images with definity:time-related changesof contrast—enhanced appearance in rabbit VX2 tumor under extra-low acoustic power[J].Eur J Radiol,2005;56(1):60-65.
[16]Kim YI, Chung JW, Park JH, et al. Intraarterial gene delivey in rabbit hepatic tumors:transfection with nonviral vector by using iodized oil emulsion[J].Radiology,2006;240(3):771-777.
[17]Burgener FA, Violante MR.Comparison of hepatic VX2-carcinomas after intra-arterial, intraportal and intraparenchymal tumor cell injection. An angiographic and computed tomographic study in the rabbit[J]. Invest Radiol, 1979,14(5):410-414.
[18]Mitsumori M, Hiraoka M, ShibataT, et al. Targeted hyperthermia using dextran magnetite complex:a new treatment modality for liver tumors [J].Hepatogastroenterology,1996:43(12):1431-143.
[19]Terayama N, Terada T, Nakanuma Y. A morphometric and immunohlstochemical study on angiogenesis of human metastatic carcinomas of the liver[J]. Hepatology, 1996,24(4):816-819.
[20]Gervaz P, Scholl B, Mainguene C, et al. Angiogenesis of liver metastases: role of sinusoidal endothelial cells[J]. Dis Colon Rec turn,2000,43(7):980-986.
[21]Paku S, Lapis K. Morphological aspects of angiogenesis in experimental liver metastases[J]. Am J Pathol,1993,143(3):926-936.
[22]Terayama N, Terada T, Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue [J]. Histopathology, 1996,29(1):37-43.
[23]Blomley MJ, Coulden R, Dawson P, et al. Liver Perfusion studied with Ultrafast CT[J]. J Comput Assist Tomogr,1995,19(3):424-433.
[24]Komemushi A, Tanigawa N, Kojima H, et al. CT Perfusion of the liver during selective hepatic arteriography:Pure arterial blood Perfusion of liver tumor and Parenchyma[J]. Radiat Med,2003,21(6):246-251.
[25]Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumor [J]. Phys Med Biol,2001,46(12):3161-3175.
[26]Cenie A, Nabavi DG,Craen RA, et al. Dynamic CT measurement of cerebral blood flow:a validation study[J]. AJNR Am J Neuroradiol,1999;20(1):63-68.
[27]王爽,赵心明,林蒙,等.原发性肝脏肿瘤的CT灌注研究[J].中国医学影像技术,2006,22(1)：95-98.
[28]文利,丁仕义,周代全等.正常肝脏CT灌注的研究[J].第三军医大学学报,2002,24(6)：943-947.
[29]时高峰,王琦,许茜,等.大鼠Walker-256肝微小转移癌模型的CT灌注成像研究[J].中国医学影像技术,2006,22(1)：35-38.
[30]Zhang J, Wang R, Wang M, et al. Experimental study of multi-slice spiral CT Perfusion imaging in VX2 soft-tissue tumor of rabbits[J]. J Huazhong Univ Sci Technolog.Med Sci,2006,26(3):341-343.
[31]Kapanen MK, Halavaara JT, Hakkinen AM. Assessment of vascular physiology of tumorous livers:comparison of two different methods[J]. Acad Radiol, 2003,10(9):1021-1029.
[1]Folkman J. Angiogenesis and breast caneer[J].J Clin oncol,1994,12(3):441-448.
[2]Blood CH, Zetter BR. Thmor interactions with vasculature angiogenesis and tumnor metastasis[J].Biochem Biophys Acta,1990,1032(1):89-95.
[3]Dezso K, Bugyik E, Papp V,et al.Development of arterial blood supply in experimental liver [J]. Am J Pathol.2009,175(2):835-843.
[4]Zhang N, Wang L, Liang Y,et al.The antiangiogenic effects of tyroservatide on animal models of hePatocellular carcinoma[J].J Cancer Res Clin Oncol. 2009,135(10):1447-1453.
[5]Folkman J.Tumor angiogenesis therapeutic implications [J]. New Engl J Med, 1971,285(12):1182-1189.
[6]Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotie cell death[J]. Cell Death Differ,1999; 6(11):1028-1031
[7]Varghese J, Chattopadhaya S, Sarin A. Inhibition of p38 kinase reveals a TNF2α2 mediated, caspase dependent, apoptotic death pathway in a human myelomonocyte cell line[J]. J Immunol,2001; 166(11):6570-6577.
[8]林春龙,张珍祥.FAK反义寡核苷酸促进人肺动脉平滑肌细胞凋亡[J].中国病理生理杂志,2006,22(2)：288-293.
[9]LIovet JM, Bruix J. Sorafenib in advanced hepatocellular carcinoma [J].N Engl J Med,2008,359(2):378-390.
[10]秦叔逵,龚新雷.索拉非尼治疗原发性肝癌的研究进展[J].临床肿瘤学杂志,2008,13(12)：1057-1068.
[1]张成武,赵大建,胡智明,等。原发性肝癌经肝动脉栓塞化疗术后预后指标的多因素分析[J]。肝胆胰外科杂志,2007,19(6)：376-379.
[2]吴孟超.原发性肝癌外科综合治疗的现状和展望[J].。中华外科杂志,2004,42(1)：13-15.
[3]Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery[J]. Ann Surg Oncol,2003,10: 355-362.
[4]Liao XF, Yi JL, Li XR, et al. Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization[J]. World J Gastroenterol.2004,10(13): 1885-1889.
[5]Vamesu S. Angiogenesis and tumor grading in primary breast cancer patients:analysis of 158 needle core biopsies[J]. Rom J MorPhol Embryol, 2006,47(3):251-257.
[6]Weidner N.Current Pathologic methods for measuring intratumoral microvessel density with breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-180.
[7]Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion[J]. Cancer,1991,67(3):385-391.
[8]Maio ED, Fiore F, Daniele B, et al. Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma:a review of literature[J]. Critical Reviews in Oncology/Hematology,2003,46(2):285-295.
[9]Maki S, Konno T,Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium[J]. Cancer,1985,56(3):751-757.
[10]崔俊,韩铭钧,杨冬华,等。碘油CT对肝癌诊断及疗效判断的价值[J]。世界华人消化杂志,2000,8(6)：837-839.
[11]Bartolozzi C, Lencioni R,Caramella D,et al.Hepatocellular carcinoma:CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection[J]. Radiology,1994,191(1):123-128.
[12]肖运平,肖恩华,罗建光,等。MR弥散成像在肝细胞癌经导管动脉化疗栓塞术后疗效评价中的价值[J]。中国医学影像技术,2008,24(2)：270-273.
[13]Van Beers BE, Lecote I,Materne R,et al. Hepatic perfusion parameters in chronic liver disease:dynamic CT measurements correlated with disease severity[J].AJR,2001,176(4):667-673.
[14]王爽,赵心明,林蒙,等。肝脏CT灌注成像在肝癌早期诊断中的价值[J]。放射学实践,2008,23(2)：200-284.
[15]Taushima Y, Funabasama S,Aoki J,et al.Quantitative perfusion map of malignant liver tumors,created from dynamic computed tomography data [J].Acad Radiol,2004,11(2):215-223.
[16]Kim YB, Park YN, Park C. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization[J]. Histopathology,2001,38(2): 160-166.
[17]郭吉刚,郭顺林,杜富会,等.原发性肝癌TACE治疗前后血清VEGF含量的变化[J].中国临床医学影像杂志,2003,14(3)：181-183.
[18]Kim KW, Bae SK, Lee OH, et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma[J]. Cancer Res,1998,58(4):348-351.
[19]Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma:a prospective study [J]. J Clin Oncol,2002,20(14):1775-1785.
[20]Borgstrom P, Hillan K, Sriramaro P, et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody[J]. Cancer Res,1996,56(21):4032-4039.
[21]Huang J, He X, Lin X, et al. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma[J]. Chin Med J,2000,113(5):446-448.
[22]Ren B, Hoti N, Rabasseda X, et al. The antiangiogenic and therapeutic implications of endostatin[J]. Methods Find ExP Clin Pharmacol 2003,25(2): 215-224.
[23]Cao Y, Cao R, Veitonmaki N. Kringle structures and antiangiogenesis[J]. Curr Med Chem Anticancer Agents 2002,2(3):667-681.
[24]Kuwahara K, Sasaki T, Kuwada Y, et al. Expressions of angiogenic factors in Pancreatic ductal carcinoma:a correlative study with clinicopathologic parameters and patient survival[J]. Pancreas,2003,26(4):344-349.
[25]Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J]. Nature, 2000,407(2):249-257.
[26]Ho QT, Kuo CJ. Vascular endothelial growth factor:Biology and therapeutic applications[J]. Int J Biochem & Cell Biol,2007,39(8):1349-1357.
[27]Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer[J]. Hum Pathol,1995,26(1):86-91.
[28]Pak YN, Kin YB, Yang KM, et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis[J]. Arch Pattol Lab Med,2000,124 (7):1061-1065.
[29]Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A,1998,95 (36):15809-15814.
[30]CamP ER, Yang A, Liu WB, et al. Combined anti-vascular effects of VEGFR-2 blockade and inhibition of nitric oxide[J]. J Am Coll Surgeons,2005,201(3): 82-87.
[31]Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors[J]. Cancer Cell,2005,8(3):299-309.
[32]Cheung AMY, Brown AS, Cucevic V, et al. Detecting Vascular Changes in Tumour Xenografts Using Micro-Ultrasound and Micro-CT Following Treatment with VEGFR-2 Blocking Antibodies [J]. Ultrasound in Med & Biol. 2007,33(8):1259-1268.
[33]柏斗胜,钱海鑫,秦磊,等.血管形成抑制剂TNPO470对小鼠肝癌术后复发和转移防治的研究[J].实用临床医药杂志,2004,8(1)：45-46.
[34]Drixler TA, Rinkes IH, Ritchie ED, et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy[J]. Cancer Res,2000,60 (16):1761-1765.
[35]Abdollahi A, Hlatky L b, Peter EH. Endostatin:The logic of antiangiogenic therapy[J]. Drug Resistance Updates,2005,8(1):59-74.
[36]Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1[J]. J Biol Chem,2002,277 (19):16464-16469.
[1]陈光斌,邹文远,李金科,等.螺旋CT灌注成像评价肝细胞癌TACE术后活性灶血供[J].郧阳医学院学报,2007,26(4)：206-209.
[2]聂永康,蔡祖龙.毛细血管灌注及通透性的CT测量及其临床应用[J].中国医学影像学杂志,2001,9(3)：211-218.
[3]Van BE, Leconte I, Materne R, et al. Hepatic perfusion parameters in chronic liver disease dynamic CT measurements correlated with disease severity[J]. AJR Am J Roentgenol,2001,176 (3):667-673.
[4]Leen E, Goldberg JA, Angerson MJ,et al. Potential role of Doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy [J].Lancet,2000,355(9197):34-37.
[5]Padhani AR.Dynamic contrast-enhanced MRI studies in human tumours[J].BrJ Radiol,1999,72(857):427-431.
[6]Hulka CA, Edmister WB, Snuth BL, et al.Dynamic echo-planar imaging of the breast:experience in diagnosing breast carcinoma and correlation with tumor angiogenesis[J].Radiology,1997,205(3):837-842.
[7]RazaS,Baum JK.Solid breast lesions:evaluation with power Doppler US [J].Radiology,1997,203(1):164-168.
[8]Blomley MJ, Lim AK, Harvey CJ, etal. Liver microbubble transit time Compared with histology and Child-Pugh score in diffuse liver disease:a cross sectional study[J].Gut,2003,52(8):1188-1193.
[9]Miles KA.Tumour angiogenesis and its relation to contrast enhancement on computed tomography:a review[J].Eur J Radiol,1999,30(3):198-205.
[10]Hirata M, Sugawara Y, Murase K, et al. Evaluation of optimal scan duration and end time in cerebral CT perfusionstudy[J].Radiat Med,2005,23(5):351-363.
[11]Miles KA.Measurement of tissue perfusion by dynamic computed tomography [J].Br J Radiol,1991,4(761):409-412.
[12]Miles KA, Hayball M, Dixon AK.Colour perfusion imaging:a new application of computed tomography [J].Laneet,1991,337(8742):643-645.
[13]Miles KA, Hayball MP, Dixon AK.Functional images of hepatic perfusion obtained with dynamic CT[J].Radiology,1993,188(2):405-411.
[14]Miles KA, Hayball MP, Dixon AK. Measurement of human pancreatic perfusion usingd dynamic computed tomography ywith perfusion imaging[J]. Br J Radiol,1995,68(809):471-475.
[15]Terayama N, Terada T, Nakanuma Y. A morphometric and immunohlstochemical study on angiogenesis of human metastatic carcinomas of the liver[J]. Hepatology,1996, 24(4):816-819.
[16]Gervaz P, Scholl B, Mainguene C, et al. Angiogenesis of liver metastases: role of sinusoidal endothelial cells[J]. Dis Colon Rec turn,2000,43(7): 980-986.
[17]Paku S, Lapis K. Morphological aspects of angiogenesis in experimental liver metastases[J]. Am J Pathol,1993,143(3):926-936.
[18]Terayama N, Terada T, Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue [J]. Histopathology, 1996,29(1):37-43.
[19]王爽,赵心明,林蒙,等.原发性肝脏肿瘤的CT灌注研究[J].中国医学影像技术,2006,22(1)：95-98.
[20]文利,丁仕义,周代全等.正常肝脏CT灌注的研究[J].第三军医大学学报,2002,24(6)：943-947.
[21]Li Z,Huang, Li S,et al.Blood supply of liver metastasis[J]. Beijing Da Xue Xue Bao,2008,40(2),146-150.
[22]Meijerink MR,Waesberghe JH,Weide L. Total-liver-volume perfusion CT using 3D image for fusion to improve detection and characterization of liver metastases[J]. Eur Radiol,2008,18(10):2345-2354.
[23]Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment[J]. Drugs Today(Barc),2005,41(12): 773-784.
[24]Beeram M, Patnaik A, Rowlnsky EK. Regulation of c-Raf—1:therapeutic implications[J]. Clin Adv Hematol Oncol,2003,1(8):476-481.
[25]Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol,2006, 24(26):4293-4297.
[26]Ratain MJ, Eisen T, Stadler WM, et al.Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2006,24(16):2505-2511.
[27]Patel PH, Chaganti RS,Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer,2006,94(5):614-619.
[28]Bleumer I, Knuth A, Osterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma paients[J]. Br J Cancer.2004,90(5):985-992.
[29]Veronese ML, Mosenkis A, Flaberty KT, et al. Mechanisms of hypertension associated with BAY 43-9006[J]. J Clin Oncol,2006,24(9):1363-1369.
[30]Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma[J]. New Engl J Med,2008,359(4):378-390.
[1]Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumorcell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res,2006,66(24): 11851-11858.
[2]伍婧,罗荣城,张华,等.索拉非尼联合三氧化二砷对肝癌细胞株的抑制作用[J].南方医科大学学报,2008,28(4)：639-641.
[3]陈逢生,崔彦芝,罗荣城,等.索拉非尼联合顺铂抑制肝癌HepG2细胞生长的体外研究[J].南方医科大学学报,2008,28(9)：1684-1687.
[4]Wang Z, Zhou J, Fan J, etal. Effect of rapamycinalone andin combination with sorafenib in all orthotopic model of human hepatocellularcarcinoma[J]. Clin Cancer Res,2008,14(16):5124-5130.
[5]Strumberg D, Richly H, Hilger RA, et al. Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patientswith advanced refractory solid tumors[J]. Journal of Clinical Oncology,2005,23(5):965-972.
[6]Clark JW, Eder JP, Ryan D, et al. Safety and pharmaeokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors[J]. Clin Cancer Res,2005,11(15):5472-5480.
[7]Awada A, Hendlisz A, Gil T, et al. Phase Ⅰ safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors[J]. Br J Cancer,2005,92(10):1855-1861.
[8]Moore M, Hirte HW, Siu L, et al. Phase Ⅰ study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 439006, administered for 28 days on/7days off in patients with advanced, refractory solid tumors[J]. Ann Oncol,2005,16(10):1688-1694.
[9]Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma[J]. Cancer Sci,2008,99(1):159-165.
[10]Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma[J]. Journal of Clinical Oncology,2006,24(26):4293-4300.
[11]Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced Hepatocellular Carcinoma[J]. N Engl J Med,2008,359(4):378-390.
[12]Richly H, Henning BF, Kupsch P, et al. Results of a Phase Ⅰ trial of sorafenib(BAY 430006)in combination with doxorubicin in patients with refractory solid tumom[J]. Ann Oncol,2006,17(5):866-873.
[13]Abou-Alfa G, Johnson P, Knox J, et al. Preliminary results from a Phase Ⅱ, randomized, double-blind study of sorafenib plus doxornbiein versus placebo plus doxornbiein in patients with advanced hepatoeellular carcinoma [J]. European Journal of Cancer,2007,5(Suppl):a 3500.
[14]Abou-Alfa G, Johnson P, Knox J, et al. Sorafenib plus doxornbiein may offer better time to progression than doxornbiein alone in advanced International Congress on Anti-Cancer Treatment(ICACT),2008 [2008-11-12].
[15]隋忠国,薛宏伟,荆凡波,等.索拉非尼联合卡培他滨治疗肝细胞癌患者的临床研究[J].中国药房,2008,19(11)：848-849.
[1]Sahani DV, Holalkere NS, Mueller PR,et al. Advanced Hepatocellular Carcinoma:CT Perfusion of Liver and Tumor Tissue—Initial Experience. Radiology.2007,243(3):736-743.
[2]Cha C, DeMatteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Practice & Research Clinical Gastroenterology,2005,19(1): 25-37.
[3]钦伦秀,孙惠川,汤钊猷.原发性肝癌研究进展——2006沪港国际肝病大会纪要.中华外科杂志,2006,44(15)：1070-1074.
[4]Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991,67(4):385-391.
[5]Maio, ED, Fiore, F, Daniele,B, et al. Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma:a review of literature. Critical Reviews in Oncology/Hematology.2003,46(2),285-295.
[6]张成武,赵大建,胡智明,等.原发性肝癌经肝动脉栓塞化疗术后预后指标的多因素分析.肝胆胰外科杂志,2007,19(6)：376-379.
[7]吴孟超.原发性肝癌外科综合治疗的现状和展望.中华外科杂志,2004,42(1)：13-15.
[8]Kim YB, Park YN, Park C. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology,2001,38(3): 160-166.
[9]郭吉刚,郭顺林,杜富会,等.原发性肝癌TACE治疗前后血清VEGF含量的变化.中国临床医学影像杂志,2003,14(3)：181-183.
[10]Kim KW, Bae SK, Lee OH, et al. Insulin-like growth factor Ⅱ induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res,1998,58(4):348-351.
[11]Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma:a prospective study. J Clin Oncol,2002,20(5):1775-1785.
[12]Borgstrom P, Hillan K, Sriramaro P, et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody. Cancer Res,1996,56(6):4032-4039.
[13]Huang J, He X, Lin X, et al. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma. Chin Med J,2000,113(5):446-448.
[14]Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol,2003,10(3): 355-362.
[15]Liao XF, Yi JL, Li XR, et al. Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol.2004,10(13): 1885-1889.
[16]Folkman J. Tumour angiogenesis:a possible control point in tumor growth. Ann Intern Med 1975; 82(1):96-100.
[17]廖晓锋,易继林,张伟杰,等.兔肝癌肝动脉栓塞后肿瘤血管生成的变化.中华实验外科杂志,2004,21(10)：1173-1175.
[18]Folkman J, Shing Y. Angiogensesis. J Biol Chem,1992,267(16):10931-10934
[19]Conti CJ. Vascular endothelial growth factor:regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. Oncologist 2002,7(Suppl3):4-11.
[20]Bandoh N, Hayashi T, Takahara M, et al. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis. Cancer Lett 2004,208(2): 215-225.
[21]Ren B, Hoti N, Rabasseda X, et al. The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol 2003; 25: 215-224
[22]Cao Y, Cao R, Veitonmaki N. Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents 2002,2(4):667-681.
[23]Kuwahara K, Sasaki T, Kuwada Y, et al. Expressions of angiogenic factors in pancreatic ductal carcinoma:a correlative study with clinicopathologic parameters and patient survival. Pancreas 2003,26(3):344-349.
[24]Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature,2000, 407(3):249-257.
[25]Ho QT, Kuo CJ. Vascular endothelial growth factor:Biology and therapeutic applications. Int J Biochem & Cell Biol,2007(39):1349-1357.
[26]Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol,1995,26(1):86-91.
[27]Pak YN, Kin YB, Yang KM, et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pattol Lab Med,2000,124 (7):1061-1065.
[28]Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A,1998,95(18):15809-15814.
[29]Hanahan D, Folkman J. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis. Cell,1996,86(3):353-364.
[30]Camp ER, Yang A, Liu WB, et al. Combined anti-vascular effects of VEGFR-2 blockade and inhibition of nitric oxide. J Am Coll Surgeons,2005,201(3): 82-91.
[31]Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell,2005,8(3):299-309.
[32]Cheung AMY, Brown AS, Cucevic V, et al. Detecting Vascular Changes in Tumour Xenografts Using Micro-Ultrasound and Micro-CT Following Treatment with VEGFR-2 Blocking Antibodies. Ultrasound in Med & Biol. 2007,33(8):1259-1268.
[33]柏斗胜,钱海鑫,秦磊,等.血管形成抑制剂TNPO470对小鼠肝癌术后复发和转移防治的研究.实用临床医药杂志,2004,8(1)：45-46.
[34]Drixler TA, Rinkes IH, Ritchie ED, et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res,2000,60 (16):1761-1765.
[35]Abdollahi A, Hlatky L b, Peter EH. Endostatin:The logic of antiangiogenic therapy. Drug Resistance Updates,2005,8(1):59-74.
[36]Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem,2002,277 (19): 16464-16469.
[37]Sophie JB, Melissa RS, Joel MR, et al. Pharmacokinetics of Intravitreal Bevacizumab (Avastin). Ophthalmology,2007,114(9):855-859.
[38]Sophie JB, Melissa RS, Joel MR, et al. Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). Ophthalmology 2007,114(13):2179-2182.
[39]Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006,26(5):495-511.
[40]Abdollahi A, Hlatky L b, Peter EH. Endostatin:The logic of antiangiogenic therapy. Drug Resistance Updates,2005,8(1):59-74.
[41]Czito GB, Bendell JC, Willett CG Bevacizumab, Oxaliplatin, and Capecitabine With Radiation Therapy in Rectal Cancer:Phase I Trial Results. Int J Radiat oncol,2007,68(2):472-478.
[42]Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography:a review. Eur J Radiol,1999,30 (3):198-205.
[43]Tsushima Y, Funabasama S, Aoki J, et al. Quantitative Perfusion Map of Malignant Liver Tumors, Created From Dynamic Computed Tomography Datal. Academic Radiology,2004,11(2):215-223.
[44]陈光斌,邹文远,李金科,等.螺旋CT灌注成像评价肝细胞癌TACE术后 活性灶血供.郧阳医学院学报,2007,26(4)：206-209.
[45]聂永康,蔡祖龙.毛细血管灌注及通透性的CT测量及其临床应用.中国医学影像学杂志,2001,9(3)：211-218.
[46]Van BE, Leconte I, Materne R, et al. Hepatic perfusion parameters in chronic liver disease dynamic CT measurements correlated with disease severity. AJR Am J Roentgenol,2001,176 (3):667-673.
[47]肖恩华,胡国栋,李锦清,等.肝细胞癌化疗栓塞方法和肿瘤坏死.临床放射学杂志,2000,19(8)：513-515.
[48]Yamada N, Imakita S, Sakuma T, et al. Intracranial calcificationon gradient echo phase images:depiction of diam agnetic susceptibility. Radiology,1996, 198(1):171-178.
[49]Sehgal V, Delproposto Z, HaackeEM, et al.Clinical applications of neuroimaging with susceptibility weighted imaging[J]. J Magn Reson imaging,2005,22(3):439-450.
[50]Sehgal V, Delproposto Z, Haddar D, et al. Susceptibility weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses[J]. J Magn Reson Imaging,2006,24(1):41-51.
[51]刘亚欧,杨延辉,李坤成.磁敏感加权成像在中枢神经系统的临床应用[J].医学影像学杂志,2007,17(2)：210-212.
[52]Takeuchi M, Matsuzaki K, Nishitani H. Susceptibility-weighted MRI of endometrioma:Preliminary results[J].AJR Am Roentqenol,2008,191 (5):1366-1370.